» Authors » Eric A Ertel

Eric A Ertel

Explore the profile of Eric A Ertel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 58
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer E, Croxford A, Gnerre C, Kulig P, Murphy M, Jacob E, et al.
J Med Chem . 2024 May; 67(10):8077-8098. PMID: 38727100
Migration of immune cells to sites of inflammation is a critical step in the body's response to infections but also during autoimmune flares. Chemokine receptors, members of the GPCR receptors,...
2.
Marchesin V, Monnier L, Blattmann P, Chevillard F, Kuntz C, Forny C, et al.
Sci Adv . 2024 Mar; 10(9):eadk1814. PMID: 38427726
Three distinct pharmacological corrector types (I, II, III) with different binding sites and additive behavior only partially rescue the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) folding and trafficking defect observed...
3.
Meyer E, Aanismaa P, Ertel E, Huhn E, Strasser D, Rey M, et al.
J Med Chem . 2023 Mar; 66(6):4179-4196. PMID: 36883854
The CXCR3 chemokine receptor is a G protein-coupled receptor mainly expressed on immune cells from the lymphoid lineage, including activated T cells. Binding of its inducible chemokine ligands CXCL9, CXCL10,...
4.
Forny C, Sube R, Ertel E
J Vis Exp . 2018 Nov; (140). PMID: 30394391
Spontaneously contracting syncytia of cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CM) are a useful model of human cardiac physiology and pharmacology. Various methods have been proposed to record this...
5.
Bezencon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, et al.
J Med Chem . 2017 Nov; 60(23):9769-9789. PMID: 29116786
We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for...
6.
Bezencon O, Remen L, Richard S, Roch C, Kessler M, Ertel E, et al.
Bioorg Med Chem Lett . 2017 Oct; 27(23):5326-5331. PMID: 29074257
We identified and characterized a series of pyrrole amides as potent, selective Ca3.2-blockers. This series culminated with the identification of pyrrole amides 13b and 26d, with excellent potencies and/or selectivities...
7.
Bezencon O, Siegrist R, Heidmann B, Pozzi D, Stamm S, Remen L, et al.
Chimia (Aarau) . 2017 Oct; 71(10):722-729. PMID: 29070417
We describe the discovery and optimization of new, brain-penetrant T-type calcium channel blockers. We present optimized compounds with excellent efficacy in a rodent model of generalized absence-like epilepsy. Along the...
8.
Bezencon O, Remen L, Richard S, Roch C, Kessler M, Moon R, et al.
Bioorg Med Chem Lett . 2017 Oct; 27(23):5322-5325. PMID: 29066309
We identified and characterized a series of pyrazole amides as potent, selective Ca3.1-blockers. This series culminated with the identification of pyrazole amides 5a and 12d, with excellent potencies and/or selectivities...
9.
Surivet J, Zumbrunn C, Bruyere T, Bur D, Kohl C, Locher H, et al.
J Med Chem . 2017 Apr; 60(9):3776-3794. PMID: 28406300
There is an urgent unmet medical need for novel antibiotics that are effective against a broad range of bacterial species, especially multidrug resistant ones. Tetrahydropyran-based inhibitors of bacterial type II...
10.
Panchaud P, Bruyere T, Blumstein A, Bur D, Chambovey A, Ertel E, et al.
J Med Chem . 2017 Apr; 60(9):3755-3775. PMID: 28406299
Our strategy to combat resistant bacteria consisted of targeting the GyrB/ParE ATP-binding sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotics. Screening around the...